EXPO
#First of all, in general I think we would expect acquisitions to be relatively small.
We think that focusing on us acting as one Company and having a certain kind of culture makes a very large acquisition risky to that so we would focus on a smaller acquisition, so these are more seed acquisitions.
A pipeline may not be quite the best way of describing that.
We always have a few in every year, we have quite a number of companies we look at and often get to the point of making offers on some.
But as we have explained before there are certain areas we are focused on.
They continue to be in the health, sort of pharmaceutical area where we think we could provide high-value toxicology, epidemiology and so forth in that space.
They are also in the computer science space, embedded software and some data analytics related to that.
Those are some of the primaries we have looked at, but I think it would be misleading for us to indicate we have a pipeline of acquisitions.
We haven't done one since 2002, but we are very open to doing the right kind of acquisition as long as we get a company at the right stage, where it's a seed for future growth and where they've got a leadership team that's going to continue to drive the business as opposed to one that is looking for retirement.
Thank you.
Thank you very much.
